Radiopharm Theranostics Limited (RADX)

NASDAQ: RADX · Real-Time Price · USD

6.79

-0.31 (-4.37%)

At close: Sep 18, 2025, 4:00 PM EDT

6.80

+0.01 (0.15%)

After-hours: Sep 18, 2025, 6:56 PM EDT

Radiopharm Theranostics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Operating Revenue	3.63	0.3	0.29	-	-
Other Revenue	9.77	1.66	5.92	-	-
Revenue	13.4	1.96	6.21	-	-
Revenue Growth (YoY)	584.21%	-68.46%	-	-	-
Cost of Revenue	3.59	21.61	19.53	7.49	-
Gross Profit	9.81	-19.65	-13.32	-7.49	-
Selling, General & Admin	14.64	13.04	12.23	7.64	0.3
Research & Development	27.52	-	-	-	-
Operating Expenses	44.05	15.68	15.27	12.44	1.16
Operating Income	-34.24	-35.33	-28.59	-19.93	-1.16
Interest Expense	-0.07	-0.64	-0.09	-9.35	-
Interest & Investment Income	-	0.05	0.15	0.01	-
Currency Exchange Gain (Loss)	0.14	0.09	-0.26	-1.11	-0
EBT Excluding Unusual Items	-34.17	-35.83	-28.79	-30.38	-1.16
Gain (Loss) on Sale of Assets	-	-1.69	-	-	-
Asset Writedown	-	-1.48	-3.1	-	-
Other Unusual Items	-4.07	-8.86	-2.68	-	-
Pretax Income	-38.24	-47.85	-34.57	-30.38	-1.16
Income Tax Expense	0.1	0.1	0.04	0.04	-
Earnings From Continuing Operations	-38.34	-47.95	-34.61	-30.42	-1.16
Minority Interest in Earnings	1.64	-	-	-	-
Net Income	-36.7	-47.95	-34.61	-30.42	-1.16
Net Income to Common	-36.7	-47.95	-34.61	-30.42	-1.16
Shares Outstanding (Basic)	2,085	386	306	181	-
Shares Outstanding (Diluted)	2,085	386	306	181	-
Shares Change (YoY)	439.62%	26.36%	68.74%	-	-
EPS (Basic)	-0.02	-0.12	-0.11	-0.17	-
EPS (Diluted)	-0.02	-0.12	-0.11	-0.17	-
Free Cash Flow	-36.65	-22.98	-23.25	-9.91	-0.08
Free Cash Flow Per Share	-0.02	-0.06	-0.08	-0.06	-
Gross Margin	73.18%	-	-214.52%	-	-
Operating Margin	-255.53%	-1803.82%	-460.41%	-	-
Profit Margin	-273.90%	-2448.23%	-557.36%	-	-
Free Cash Flow Margin	-273.47%	-1173.12%	-374.36%	-	-
EBITDA	-31.65	-32.2	-25.29	-16.94	-
EBITDA Margin	-236.16%	-	-	-	-
D&A For EBITDA	2.6	3.13	3.3	2.98	-
EBIT	-34.24	-35.33	-28.59	-19.93	-1.16
EBIT Margin	-255.53%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q